E (c (RGDfK) ) 2

• Description:

  E (c (RGDfK) ) is an αvβ3 integrin-specific binding moiety with tumor targeting properties. Increased uptake of E (c (RGDfK) ) in human ovarian cancer OVCAR-3 xenograft tumors may be useful in cancer research[1].

• UNSPSC:

  12352209

• Target:

  Integrin

• Type:

  Peptides

• Related Pathways:

  Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/e-c-rgdfk.html

• Purity:

  99.82

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N1)=O)CC(O)=O)=O)=O)CCCNC(N)=N)=O)CCCCNC([C@@H](N)CCC(NCCCC[C@@H]2NC([C@H](NC([C@@H](NC(CNC([C@@H](NC2=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)CC3=CC=CC=C3)=O)=O)=O)[C@H]1CC4=CC=CC=C4

• Molecular Formula:

  C59H87N19O16

• Molecular Weight:

  1318.44

• References & Citations:

  [1]Polyak D, et al. Development of PEGylated doxorubicin‐E‐[c (RGDfK) 2] conjugate for integrin‐targeted cancer therapy[J]. Polymers for Advanced Technologies, 2011, 22 (1) : 103-113.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category:

  Peptides

• Clinical Information:

  No Development Reported

• CAS Number:

  [250612-47-6]